Previous 10 | Next 10 |
Integra LifeSciences (NASDAQ:IART) has appointed Jan De Witte as President and CEO, and a member of its Board of Directors. De Witte will join Integra prior to the end of 2021. He succeeds Peter Arduini, who is stepping down to join GE Healthcare as President and CEO. Most recently, De Witte ...
PRINCETON, N.J., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, today announced that it has appointed Jan D. De Witte as its next President and Chief Executive Officer. Mr. De Witte succeeds Peter ...
PRINCETON, N.J., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, will release third quarter 2021 financial results on Tuesday, November 2, 2021, prior to the market open. In conjunction with the ear...
Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes tradi...
Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes tradi...
Integra Lifescience Holdings (IART) is our growth stock of the week. The company has shown an ability to consistently grow by entering new markets and raise margins. Further, the stock is quite attractive from a value perspective. Typically, when analyzing stocks, there’s a tradeo...
Smith & Nephew has been losing share in major joints, but a new cementless knee implant, the Cori robotic system, and an increased focus on ambulatory centers could reverse that. Extremities and joint repair offer attractive growth opportunities, as does the Tula ear tube system, ...
Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes tradi...
Integra posted strong second quarter results, with not only better than expected revenue and much better than expected operating earnings, but respectable growth from Q2'19 levels as well. The Codman neurosurgery business is performing very well, and should get a further boost from up...
Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes tradi...
News, Short Squeeze, Breakout and More Instantly...
Integra LifeSciences Holdings Corporation Company Name:
IART Stock Symbol:
NASDAQ Market:
Integra LifeSciences Holdings Corporation Website:
2024-07-30 10:00:08 ET Richard Newitter from Truist Financial issued a price target of $26.00 for IART on 2024-07-30 08:59:00. The adjusted price target was set to $26.00. At the time of the announcement, IART was trading at $24.59. The overall price target consensus is ...
2024-07-30 06:30:09 ET Citigroup analyst issues SELL recommendation for IART on July 30, 2024 03:24AM ET. The previous analyst recommendation was Neutral. IART was trading at $25.42 at issue of the analyst recommendation. The overall analyst consensus : SELL. Current...
2024-07-30 06:00:06 ET Joanne Wuensch from Citigroup issued a price target of $23.00 for IART on 2024-07-30 03:24:00. The adjusted price target was set to $23.00. At the time of the announcement, IART was trading at $25.42. The overall price target consensus is at $47.00...